Computational studies and peptidomimetic design for the human p53-MDM2 complex

Proteins: Structure, Function and Genetics

Volumn 58, Issue 1, 2005, Pages 222-234

  Zhong, Haizhen ^a   Carlson, Heather A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

peptide; AMBER; Escape mutants; Free energy calculation; HDM2; Inhibitor; Molecular dynamics simulation; Protein mimic

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCULATION; CANCER RESEARCH; CELL GROWTH; COMPLEX FORMATION; COMPUTER SIMULATION; CONTROL SYSTEM; DRUG DESIGN; ENERGY; HUMAN; HUMAN CELL; HYDROPHOBICITY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; TUMOR CELL;

BINDING SITES; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR MIMICRY; MUTAGENESIS, SITE-DIRECTED; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 10844238962     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.20275     Document Type: Article

References (44)

1. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
2. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 1994;91:3602-3606.
3. Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 1994;265:2091-2093.
4. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857-860.
5. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
6. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-83.
7. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, Doglioni C, Bevilacqua G, Barbareschi M. MDM2 gene alterations and MDM2 protein expression in breast carcinomas. J Pathol 1995;175:31-38.
8. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-2739.
9. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993;82:2617-2623.
10. Wasylyk C, Salvi R, Argentini M, Dureuil C, Delumeau I, Abecassis J, Debussche L, Wasylyk B. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999;18:1921-1934.
11. Böttger A, Böttger V, García-Echeverría C, Chène P, Hochkeppel HK, Sampson W, Ang K, Howard SF, Picksley SM, Lane DP. Molecular characterization of the HDM2-p53 interaction. J Mol Biol 1997;269:744-756.
12. García-Echeverría C, Chène P, Blommers MJ, Furet P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J Med Chem 2000;43:3205-3208.
13. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848.
14. Massova I, Kollman PA. Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies. J Am Chem Soc 1999;121:8133-8143.
15. Sandvoss LM, Carlson HA. Conformational behavior of β-proline oligomers. J Am Chem Soc 2003;125:15855-15862.
16. Huck BR, Fisk JD, Guzei ID, Carlson HA, Gellman SH. Secondary structural preferences of 2,2-disubstituted pyrrolidine-4-carboxylic acid oligomers: β-peptide foldamers that cannot form internal hydrogen bonds. J Am Chem Soc 2003; 125:9035-9037.
17. Seebach D, Matthews JL. β-peptides: a surprise at every turn. Chem Commun (Camb)1997:2015-2022.
18. DeGrado WF, Schneider JP, Hamuro Y. The twists and turns of beta-peptides. J Peptide Res 1999;54:206-217.
19. Cheng RP, Gellman SH, DeGrado WF. β-peptides: from structure to function. Chem Rev 2001;101:3219-3232.
20. Gellman SH. Foldamers: a manifesto. Acc Chem Res 1998;31:173-180.
21. Kirshenbaum K, Zuckermann RN, Dill KA. Designing polymers that mimic biomolecules. Curr Opin Struct Biol 1999;9:530-535.
22. Hill DJ, Mio MJ, Prince RB, Hughes TS, Moore JS. A field guide to foldamers. Chem Rev 2001;101:3893-4011.
23. Case DA, Pearlman DA, Caldwell JW, Cheatham TE III, Ross WS, Simmerling CL, Darden TA, Merz KM, Stanton RV, Cheng AL, Vincent JJ, Crowley M, Tsui V, Radmer RJ, Duan Y, Pitera J, Massova I, Seibel GL, Singh UC, Weiner PK, Kollman PA. AMBER 6.0. San Francisco: University of California at San Francisco; 1999.
24. Cornel WD, Cieplak P, Bayly CI, Gould IR, Merz JKM, Ferguson DM, Spellmeyer DM, Fox T, Caldwell JW, Kollman PA. A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J Am Chem Soc 1995;117:5179-5197.
25. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274:948-953.
26. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926-935.
27. Molecular Operating Environment, Version MOE 2002.03. Montreal, Canada: Chemical Computing Group, Inc.; 2002.
28. Darden T, York D, Pedersen L. Particle mesh Ewald: an N · log(N) method for Ewald sums in large systems. J Chem Phys 1993;98:10089-10092.
29. Bashford D, Case DA. Generalized Born models of macromolecular solvation effects Annu Rev Phys Chem 2000;51:129-152.
30. Tsui V, Case DA. Molecular dynamics simulations of nucleic acids with a Generalized Born solvation model. J Am Chem Soc 2000;122:2489-2498.
31. Jayaram B, Sprous D, Beveridge DL. Solvation free energy of biomacromolecules parameters for a modified Generalized Born model consistent with the AMBER force field. J Phys Chem B 1998;102:9571-9576.
32. Sanner MF, Olson AJ, Spehner JC. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 1996;38:305-320.
33. Case DA. Normal-mode analysis of protein dynamics. Curr Opin Struct Biol 1994;4:285-290.
34. Kottalam J, Case DA. Langvin modes of macromolecules: applications to Crambin and DNA hexamers. Biopolymers 1990;29:1409-1421.
35. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994;9:2523-2529.
36. Portefaix JM, Thebault S, Bourgain-Guglielmetti F, Del Rio M, Granier C, Mani JC, Navarro-Teulon I, Nicolas M, Soussi T, Pau B. Critical residues of epitopes recognized by several anti-p53 monoclonal antibodies correspond to key residues of p53 involved in interactions with the mdm2 protein. J Immunol Methods 2000;244:17-28.
37. Kortemme T, Baker D. A simple physical model for binding energy hot spots in protein-protein complexes. Proc Natl Acad Sci USA 2002;99:14116-14121.
38. Freedman DA, Epstein CB, Roth JC, Levine AJ. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol Med 1997;3:248-259.
39. Chen J, Marechal V, Levine AJ. Mapping of the p53 and MDM-2 interaction domains. Mol Cell Biol 1993;13:4107-4114.
40. Leng P, Brown DR, Shivakumar CV, Deb S, Deb S. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene 1995;10:1275-1282.
41. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-648.
42. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996;3:927-933.
43. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, Öhman L, Greene GL, Gustafsson J-A, Carlquist M. Molecular basis of agonism and antagonismin the oestrogen receptor. Nature 1997;389:753-758.
44. Kritzer JA, Lear JD, Hodsdon ME, Schepartz A. Helical β-peptide inhibitors of the p53-hDMZ interaction. J Am Chem Soc 2004;126:9468-9469.